JPWO2019226603A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019226603A5 JPWO2019226603A5 JP2020564923A JP2020564923A JPWO2019226603A5 JP WO2019226603 A5 JPWO2019226603 A5 JP WO2019226603A5 JP 2020564923 A JP2020564923 A JP 2020564923A JP 2020564923 A JP2020564923 A JP 2020564923A JP WO2019226603 A5 JPWO2019226603 A5 JP WO2019226603A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- rna
- premirna
- polynucleotide according
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000040430 polynucleotide Human genes 0.000 claims description 84
- 108091033319 polynucleotide Proteins 0.000 claims description 84
- 239000002157 polynucleotide Substances 0.000 claims description 84
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 40
- 108020004566 Transfer RNA Proteins 0.000 claims description 30
- 239000002773 nucleotide Substances 0.000 claims description 23
- 125000003729 nucleotide group Chemical group 0.000 claims description 23
- 239000002679 microRNA Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 108091070501 miRNA Proteins 0.000 claims description 17
- 108091093142 MiR-144 Proteins 0.000 claims description 14
- 108091062895 miR-144 stem-loop Proteins 0.000 claims description 14
- 108700011259 MicroRNAs Proteins 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 239000002502 liposome Substances 0.000 claims description 12
- 239000004055 small Interfering RNA Substances 0.000 claims description 12
- 108091056924 miR-124 stem-loop Proteins 0.000 claims description 11
- -1 miR-519 Proteins 0.000 claims description 11
- 108091007772 MIRLET7C Proteins 0.000 claims description 10
- 108091027977 Mir-200 Proteins 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000002105 nanoparticle Substances 0.000 claims description 10
- 108091028066 Mir-126 Proteins 0.000 claims description 9
- 230000014509 gene expression Effects 0.000 claims description 9
- 108091044988 miR-125a stem-loop Proteins 0.000 claims description 9
- 108091049513 miR-125a-1 stem-loop Proteins 0.000 claims description 9
- 108091040046 miR-125a-2 stem-loop Proteins 0.000 claims description 9
- 108091059105 miR-216-1 stem-loop Proteins 0.000 claims description 9
- 108091045470 miR-216-2 stem-loop Proteins 0.000 claims description 9
- 108091060033 miR-298 stem-loop Proteins 0.000 claims description 9
- 108091029997 miR-328 stem-loop Proteins 0.000 claims description 9
- 108090000994 Catalytic RNA Proteins 0.000 claims description 8
- 102000053642 Catalytic RNA Human genes 0.000 claims description 8
- 102000006382 Ribonucleases Human genes 0.000 claims description 8
- 108010083644 Ribonucleases Proteins 0.000 claims description 8
- 238000003776 cleavage reaction Methods 0.000 claims description 8
- 108091028606 miR-1 stem-loop Proteins 0.000 claims description 8
- 108091074094 miR-1291 stem-loop Proteins 0.000 claims description 8
- 108091059456 miR-92-1 stem-loop Proteins 0.000 claims description 8
- 108091084336 miR-92-2 stem-loop Proteins 0.000 claims description 8
- 108091092562 ribozyme Proteins 0.000 claims description 8
- 230000007017 scission Effects 0.000 claims description 8
- 108091023037 Aptamer Proteins 0.000 claims description 7
- 108091007780 MiR-122 Proteins 0.000 claims description 7
- 108091028695 MiR-224 Proteins 0.000 claims description 7
- 108091060568 Mir-133 microRNA precursor family Proteins 0.000 claims description 7
- 108091061943 Mir-218 microRNA precursor family Proteins 0.000 claims description 7
- 108091062170 Mir-22 Proteins 0.000 claims description 7
- 108091084090 miR-106 stem-loop Proteins 0.000 claims description 7
- 108091026955 miR-1180 stem-loop Proteins 0.000 claims description 7
- 108091051828 miR-122 stem-loop Proteins 0.000 claims description 7
- 108091023685 miR-133 stem-loop Proteins 0.000 claims description 7
- 108091089860 miR-148 stem-loop Proteins 0.000 claims description 7
- 108091027943 miR-16 stem-loop Proteins 0.000 claims description 7
- 108091091751 miR-17 stem-loop Proteins 0.000 claims description 7
- 108091069239 miR-17-2 stem-loop Proteins 0.000 claims description 7
- 108091041042 miR-18 stem-loop Proteins 0.000 claims description 7
- 108091062221 miR-18a stem-loop Proteins 0.000 claims description 7
- 108091063796 miR-206 stem-loop Proteins 0.000 claims description 7
- 108091040176 miR-218 stem-loop Proteins 0.000 claims description 7
- 108091063344 miR-30b stem-loop Proteins 0.000 claims description 7
- 108091029119 miR-34a stem-loop Proteins 0.000 claims description 7
- 108091043953 miR-373 stem-loop Proteins 0.000 claims description 7
- 108091041286 miR-374 stem-loop Proteins 0.000 claims description 7
- 108091027983 miR-378-1 stem-loop Proteins 0.000 claims description 7
- 108091089716 miR-378-2 stem-loop Proteins 0.000 claims description 7
- 108091053086 miR-4458 stem-loop Proteins 0.000 claims description 7
- 108091008052 miR-449 Proteins 0.000 claims description 7
- 108091090896 miR-506 stem-loop Proteins 0.000 claims description 7
- 108091091808 miR-6775 stem-loop Proteins 0.000 claims description 7
- 108091023818 miR-7 stem-loop Proteins 0.000 claims description 7
- 108091046579 miR-888 stem-loop Proteins 0.000 claims description 7
- 108091032902 miR-93 stem-loop Proteins 0.000 claims description 7
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 6
- 108020005544 Antisense RNA Proteins 0.000 claims description 6
- 108020005004 Guide RNA Proteins 0.000 claims description 6
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 6
- 239000003184 complementary RNA Substances 0.000 claims description 6
- 108091027698 miR-18-1 stem-loop Proteins 0.000 claims description 6
- 108091090961 miR-18-2 stem-loop Proteins 0.000 claims description 6
- 108091025686 miR-199a stem-loop Proteins 0.000 claims description 6
- 108091027963 non-coding RNA Proteins 0.000 claims description 6
- 102000042567 non-coding RNA Human genes 0.000 claims description 6
- 150000003384 small molecules Chemical class 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 108091059135 miR-429 stem-loop Proteins 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 claims description 5
- 108020005098 Anticodon Proteins 0.000 claims description 3
- 108091032955 Bacterial small RNA Proteins 0.000 claims description 3
- 101100408379 Drosophila melanogaster piwi gene Proteins 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 108091008103 RNA aptamers Proteins 0.000 claims description 3
- 108020004422 Riboswitch Proteins 0.000 claims description 3
- 108020004688 Small Nuclear RNA Proteins 0.000 claims description 3
- 102000039471 Small Nuclear RNA Human genes 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 108091074487 miR-34 stem-loop Proteins 0.000 claims description 2
- 108091092493 miR-34-1 stem-loop Proteins 0.000 claims description 2
- 108091059780 miR-34-2 stem-loop Proteins 0.000 claims description 2
- 108091007422 miR-98 Proteins 0.000 claims description 2
- 108091049773 miR-14 stem-loop Proteins 0.000 claims 1
- 239000002539 nanocarrier Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 11
- 108050007957 Cadherin Proteins 0.000 description 6
- 102000000905 Cadherin Human genes 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 102100021062 Ferritin light chain Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102100032705 Keratin, type I cytoskeletal 23 Human genes 0.000 description 4
- 101710183652 Keratin, type I cytoskeletal 23 Proteins 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 4
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 4
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 description 4
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 2
- 108700020469 14-3-3 Proteins 0.000 description 2
- 102000004899 14-3-3 Proteins Human genes 0.000 description 2
- 101150094625 14-3-3zeta gene Proteins 0.000 description 2
- 108010002084 Apoferritins Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 2
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 101001027621 Homo sapiens Kinesin-like protein KIF20A Proteins 0.000 description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 2
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 description 2
- 101001062222 Homo sapiens Receptor-binding cancer antigen expressed on SiSo cells Proteins 0.000 description 2
- 102100037694 Kinesin-like protein KIF20A Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102100022678 Nucleophosmin Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 101710185022 Proteasome-activating nucleotidase 2 Proteins 0.000 description 2
- 102100029165 Receptor-binding cancer antigen expressed on SiSo cells Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 101150047061 tag-72 gene Proteins 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- JFBCSFJKETUREV-LJAQVGFWSA-N 1,2-ditetradecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCC JFBCSFJKETUREV-LJAQVGFWSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862674939P | 2018-05-22 | 2018-05-22 | |
| US62/674,939 | 2018-05-22 | ||
| PCT/US2019/033232 WO2019226603A1 (en) | 2018-05-22 | 2019-05-21 | Trna/pre-mirna compositions and use in treating cancer |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021524245A JP2021524245A (ja) | 2021-09-13 |
| JP2021524245A5 JP2021524245A5 (https=) | 2022-05-23 |
| JPWO2019226603A5 true JPWO2019226603A5 (https=) | 2022-05-23 |
| JP7545726B2 JP7545726B2 (ja) | 2024-09-05 |
Family
ID=68616101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564923A Active JP7545726B2 (ja) | 2018-05-22 | 2019-05-21 | ｔＲＮＡ／プレｍｉＲＮＡ組成物およびがん治療における使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11946049B2 (https=) |
| EP (1) | EP3796920A4 (https=) |
| JP (1) | JP7545726B2 (https=) |
| WO (1) | WO2019226603A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11702657B2 (en) | 2018-04-20 | 2023-07-18 | The Regents Of The University Of California | TRNA/pre-miRNA compositions and methods for treating hepatocellular carcinoma |
| GB201919021D0 (en) | 2019-12-20 | 2020-02-05 | Reneuron Ltd | Nucleic acid constructs for delivering polynucleotides into exosomes |
| CN110946872B (zh) * | 2019-12-30 | 2022-11-04 | 北京大学深圳医院 | miR-4491在制备治疗乳腺癌的药物中的应用 |
| AU2021255583A1 (en) * | 2020-04-14 | 2022-11-10 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and uses thereof |
| CN114058697B (zh) * | 2020-07-29 | 2023-08-18 | 四川大学华西医院 | 检测外泌体miR-6774-3p或miR-6776-5p的试剂的用途 |
| US20230407297A1 (en) * | 2020-11-03 | 2023-12-21 | The Regents Of The University Of California | Bioengineered wnt5a therapeutics for advanced cancers |
| WO2023164285A1 (en) * | 2022-02-28 | 2023-08-31 | Northwestern University | DISE-INDUCING sRNA-POLYPLEXES AND sRNA-LIPOPOLYPLEXES AND METHODS OF USING THE SAME TO TREAT CANCER |
| CN115323057A (zh) * | 2022-09-01 | 2022-11-11 | 浙江医院 | 肺癌治疗疗效相关的生物标志物 |
| CN115896295A (zh) * | 2022-12-30 | 2023-04-04 | 中国科学技术大学 | 辅助诊断胆囊炎或预测胆囊炎合并肝损伤的miRNA标志物 |
| CN117126938A (zh) * | 2023-10-08 | 2023-11-28 | 常州市第一人民医院 | 一种用于诊断膜性肾病的生物标志物及其应用方法 |
| WO2025155837A1 (en) * | 2024-01-19 | 2025-07-24 | Massachusetts Institute Of Technology | Modular microrna expression from self-replicating rna (replicons) |
| CN121406635A (zh) * | 2024-05-08 | 2026-01-27 | 西安艾领克生物科技有限公司 | 一种利用活性tRNA在大肠杆菌中嵌合表达重组小RNA的方法及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| EP3160980B1 (en) | 2014-05-28 | 2020-05-20 | The Regents of the University of California | HYBRID tRNA/pre-miRNA MOLECULES AND METHODS OF USE |
| WO2016153880A2 (en) * | 2015-03-23 | 2016-09-29 | The Regents Of The University Of California | Methods for detection of rnase activity |
| US11702657B2 (en) * | 2018-04-20 | 2023-07-18 | The Regents Of The University Of California | TRNA/pre-miRNA compositions and methods for treating hepatocellular carcinoma |
-
2019
- 2019-05-21 US US17/056,203 patent/US11946049B2/en active Active
- 2019-05-21 EP EP19806974.2A patent/EP3796920A4/en active Pending
- 2019-05-21 JP JP2020564923A patent/JP7545726B2/ja active Active
- 2019-05-21 WO PCT/US2019/033232 patent/WO2019226603A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021524245A5 (https=) | ||
| Abba et al. | MicroRNAs as novel targets and tools in cancer therapy | |
| Hosseinahli et al. | Treating cancer with microRNA replacement therapy: A literature review | |
| JP7026440B2 (ja) | ハイブリッドｔＲＮＡ／プレｍｉＲＮＡ分子および使用方法 | |
| Ivkovic et al. | microRNAs as cancer therapeutics: A step closer to clinical application | |
| Abd-Aziz et al. | Development of microRNAs as potential therapeutics against cancer | |
| Paladini et al. | Targeting microRNAs as key modulators of tumor immune response | |
| Li et al. | MicroRNAs and drug resistance in prostate cancers | |
| Sell et al. | MicroRNAs in cancer metastasis: biological and therapeutic implications | |
| Ling et al. | MicroRNAs and other non-coding RNAs as targets for anticancer drug development | |
| Ishida et al. | miRNA-based therapeutic strategies | |
| Iorio et al. | Breast cancer and microRNAs: therapeutic impact | |
| Uchino et al. | RNAi therapeutics and applications of microRNAs in cancer treatment | |
| Sempere et al. | Role of non-coding RNAs in tumor progression and metastasis in pancreatic cancer | |
| Weidle et al. | The role of micro RNAs in breast cancer metastasis: preclinical validation and potential therapeutic targets | |
| McDermott et al. | The therapeutic potential of microRNAs: disease modulators and drug targets | |
| Xue et al. | MicroRNA-targeted therapeutics for lung cancer treatment | |
| JP2017524341A5 (https=) | ||
| JPWO2019226603A5 (https=) | ||
| JP2021524245A (ja) | ｔＲＮＡ／プレｍｉＲＮＡ組成物およびがん治療における使用 | |
| Wu et al. | MiRNAs in human cancers: the diagnostic and therapeutic implications | |
| Jafri et al. | MicroRNAs as potential drug targets for therapeutic intervention in colorectal cancer | |
| Chakraborty et al. | Therapeutic microRNA delivery strategies with special emphasis on cancer therapy and tumorigenesis: current trends and future challenges | |
| Hamdy et al. | MicroRNA: Exploring Their Multifaceted Role in Cancer | |
| Tonnini et al. | The role of non-coding RNAs in pleural mesothelioma |